Gilead to Donate Experimental Coronavirus Drug Remdesivir (2)

Gilead Sciences Inc. said it’s donating 1.5 million doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients.

The drug will be offered for compassionate use, expanded access and clinical trials, and will treat patients with severe symptoms, Chairman and Chief Executive Officer Daniel O’Day said in an open letter. The company is also boosting its supply of remdesivir to more than 500,000 treatment courses by October, and to more than 1 million by the end the year. Production time has also been accelerated to six months from one year, he said.

Daniel O’Day attends a meeting in Washington, D.C. on March 2.

Photographer: Kevin Dietsch/UPI/Bloomberg

“While we are working with the utmost sense of urgency on the immediate needs before us, we are also looking forward,” he said. “Over the next weeks and months, we will be able to further increase our supplies of remdesivir as raw materials with long lead times become available for manufacture.”

The drugmaker said last week it’s switching to “expanded access” from a “compassionate use” program under which remdesivir was given. The move will accelerate its emergency use for multiple severely ill patients. More than 1,700 patients have been treated through these programs, O’Day said in the letter on Saturday.

A World Health Organization panel said in January that remdesivir was considered to be the most promising therapeutic candidate based on its broad antiviral spectrum, and existing data based on human and animal studies. The medication was developed initially for Ebola and studied in patients in Eastern Congo.

Multiple clinical trials are investigating the drug’s effects in Covid-19 patients in China and elsewhere.

Gilead Expands Access to Experimental Coronavirus Drug

(Adds other forms of uses for the drug in second paragraph.)

--With assistance from Robert Langreth.

To contact the reporter on this story:
Linus Chua in Los Angeles at lchua@bloomberg.net

To contact the editors responsible for this story:
Drew Armstrong at darmstrong17@bloomberg.net

Linus Chua, Ian Fisher

© 2020 Bloomberg L.P. All rights reserved. Used with permission.